Small Cell Lung Cancer: Page 4

Tumor mutational burden biomarker may not pass muster (again) at ASCO

In one presentation at the meeting, the company will show tumor mutational burden as part of comprehensive genomic profiling was useful for predicting tumor responsiveness to immunotherapy in a study of 3,800 women with three kinds of metastatic breast cancer: HER2-negative (ER-positive/HER2-negative), HER2-amplified, and triple-negative breast cancer. The study outlined the percentage of women with TMB mutations over 10 or 20 mutations per megabase, but it did not correlate genetic status with outcomes.

May 19, 2019

Inivata touts liquid biopsy studies

The ability of the test of circulating tumor DNA (ctDNA) to detect genetic mutations was evaluated in 264 patients with nonsquamous non-small cell lung cancer (NSCLC) in two multicenter studies. Results were published by Dr. Michael Pritchett and colleagues in the journal on April 25, following their presentation at the World Conference on Lung Cancer in September 2018.

April 25, 2019

Liquid biopsy results help TARGET cancer treatments in U.K. study

In an ideal world, all cancer patients would get a personalized treatment regimen based on the molecular profile of their particular tumor. But tissue biopsies are invasive, and results may become outdated over time as cancers evolve.

April 22, 2019